This trial compared IDegAsp with biphasic insulin aspart 30 ( BIAsp 30 ) in adults with type 2 diabetes inadequately controlled with once - or twice-daily ( OD or BID ) pre - or self-mixed insulin with or without oral antidiabetic drugs .